MannKind | MNKD - Operating Expenses

Stock Price
6.11
Daily Change
0.10 1.58%
Monthly
8.63%
Yearly
9.21%
Q1 Forecast
5.60

MannKind reported $63.35M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Adma Biologics USD 83.21M 4.02M Sep/2025
Dynavax Technologies USD 73.6M 7.41M Sep/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Halozyme Therapeutics USD 136.34M 13.06M Sep/2025
Insmed USD 403.69M 42.4M Sep/2025
MacroGenics USD 67M 8M Sep/2025
MannKind USD 63.35M 2.51M Sep/2025
Merck USD 10.72B 1.28B Sep/2025
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pfizer USD 92.8B 82.47B Sep/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Xencor USD 68.52M 8.26M Sep/2025